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Abstract
Purpose: As a foundation for a dose escalation trial, we sought to characterize duodenal and non-
duodenal small bowel organ motion between fractions of pancreatic radiation therapy.
Patients and methods: Nine patients (4 women, 5 men) undergoing radiation therapy were
enrolled in this prospective study. The patients had up to four weekly CT scans performed during
their course of radiation therapy. Pancreas, duodenum and non-duodenal small bowel were then
contoured for each CT scan. On the initial scan, a four-field plan was generated to fully cover the
pancreas. This plan was registered to each subsequent CT scan. Dose-volume histogram (DVH)
analyses were performed for the duodenum, non-duodenal small bowel, large bowel, and pancreas.
Results: With significant individual variation, the volume of duodenum receiving at least 80% of the
prescribed dose was consistently greater than the remaining small bowel. In the patient with the
largest inter-fraction variation, the fractional volume of non-duodenal small bowel irradiated to at
least the 80% isodose line ranged from 1% to 20%. In the patient with the largest inter-fraction
variation, the fractional volume of duodenum irradiated to at least the 80% isodose line ranged
from 30% to 100%.
Conclusion: The volume of small bowel irradiated during four-field pancreatic radiation therapy
changes substantially between fractions. This suggests dose escalation may be possible. However,
dose limits to the duodenum should be stricter than for other segments of small bowel.
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Background
The annual incidence of pancreatic cancer is approxi-
mately 30,000 [1]. For these patients, 5 year survival is less
than 5%[1]. Despite advances in chemotherapeutic agents
and radiation therapy techniques, there are virtually no
long term survivors among patients unable to undergo
surgical resection[1].
In principle, increasing the amount of radiation delivered
to the pancreas may improve these dismal results. Unfor-
tunately, the pancreas moves substantially with respira-
tion[2], and the surrounding organs, notably stomach
and small bowel, undergo significant volume changes
during radiation therapy [3].
Such pancreatic motion and change in surrounding nor-
mal small bowel makes dose escalation problematic. A
variety of strategies are being explored to quantify and
address issues relating to pancreatic motion, including
gating of radiation with respiration[4] and implantation
of markers to directly track organ movement[5]. However,
little work has been done to address the issue of quantify-
ing and limiting dose to the small bowel.
Much of the small bowel experiences complex motion.
The duodenum, however, is relatively fixed.
This study sought to quantify volume changes of the duo-
denum and non-duodenal small bowel within a standard-
ized pancreatic treatment volume.
Patients and methods
Nine patients undergoing radiation therapy – four with
cervical cancer and five with prostate cancer – were pro-
spectively enrolled onto an intramural protocol. Each
underwent CT simulation in the supine position in an
alpha cradle fixed to the treatment table in order to mini-
mize daily setup variation. An external radioopaque fidu-
cial marker was embedded into the cradle in the midline
superior to each patient's iliac crest around the L3 verte-
bral level. The patients then had a weekly CT scan per-
formed for up to four weeks during their course of
radiation therapy to determine inter-fraction motion. The
patients were breathing freely and were given no instruc-
tions regarding time from their last meal to the next
scheduled treatment time. Small bowel contrast was given
for all patients except for two who could not tolerate the
contrast administration. No spasmolytics were used.
The whole pancreas was contoured, and this contour was
designated gross tumor volume (GTV). Small bowel was
contoured as duodenum and non-duodenal small bowel.
Specifically, the duodenum was contoured from the
pylorus to its ascending (fourth) portion, lateral to the
head of the pancreas. All remaining small bowel to the
level of the ascending colon was designated "small bowel,
excluding duodenum." Bowel was contoured closely
along the wall of each loop on each axial slice for each
scan generated. The lumen was included in all bowel con-
tours. All contouring was manual.
A four-field plan was generated based on the initial CT
scan. The four equally-weighted fields consisted of two
AP/PA fields, measuring 15 × 10 cm, and two lateral fields,
each measuring 10 × 10 cm. The treatment plans were
designed to provide 100% coverage to the GTV based on
the initial CT scan. The initial treatment plan was then run
on each subsequent CT scan for each patient. The prescrip-
tion dose was 50.4 Gy in 1.8 Gy daily fractions.
All treatment plans were transferred using the RTOG QA
protocol to an custom treatment planning research soft-
ware platform, the Computational Environment for Radi-
otherapy Research (CERR)[6]. CERR includes: (1) an
import program which converts the widely available
AAPM/RTOG treatment planning format into a MATLAB
cell-array data object, facilitating manipulation; (2) view-
ers which display axial, coronal, and sagittal computed
tomography images, structure contours, digital films, and
isodose lines or dose colorwash, (3) a suite of contouring
tools to edit and/or create anatomical structures, and (4)
dose-volume and dose-surface histogram calculation and
display tools.
The plan and its resultant dose distributions were regis-
tered to each subsequent CT scan by keeping constant the
relative position between the beam isocenter and the
external fiducial marker embedded in the alpha cradle.
DVH and organ motion analyses were performed on the
GTV, the duodenum, non-duodenal small bowel, and
large bowel. Total volume of these organs was noted for
each CT scan (see Table 1.).
Results
Among these 9 patients, 31 total CT scans were available
for analysis. Figures 1, 2, 3 show DVHs from all patients.
These data illustrate the effects of inter-fraction motion on
coverage of duodenum and small bowel (excluding duo-
denum). The fractional volume of non-duodenal small
bowel receiving at least 80% (40 Gy) of the prescribed
dose to the pancreas varied significantly in individual
patients. Specifically, in the patient with the largest inter-
fraction variation, the fractional volume of small bowel
irradiated to at least 40 Gy ranged from 1% to 20%. In the
patient with the smallest inter-fraction variation, the frac-
tional volume of small bowel irradiated to at least 40 Gy
ranged from 11% to 12%. Both the absolute volume and
inter-fraction variation of duodenum irradiated to at least
40 Gy differed significantly compared with the rest of the
small bowel. In the patient with the largest inter-fractionRadiation Oncology 2006, 1:33 http://www.ro-journal.com/content/1/1/33
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variation, the fractional volume of duodenum irradiated
to at least 40 Gy ranged from 30 to 100%. In the patient
with the smallest inter-fraction variation, the fractional
volume of duodenum irradiated to at least 40 Gy ranged
from 60% to 100%.
Discussion
Our data present two unique findings. First, within a
standardized pancreatic treatment volume, small bowel
motion is substantial and only small volumes receive 80%
of the prescribed dose. Second, our data suggests that rel-
ative motion of the duodenum is quite distinct from the
remainder of the small bowel. Percent volumes of the
duodenum receiving 80% of the prescribed dose were far
greater than percent volumes of small bowel receiving the
same dose.
This relative immobility of the duodenum compared with
the remaining small bowel is a consequence of known
anatomy. The duodenum is fixed to the pancreas (by the
pancreatic duct) and to the gall bladder (by the common
bile duct). Additionally, near the level of the pancreas, the
duodenum is fixed by the ligament of Treitz, a suspensory
muscle arising from the stems of celiac and superior
mesenteric arteries and inserting into the third and fourth
portions of the duodenum[7]. These attachments between
duodenum and surrounding structures more directly limit
motion of the duodenum than the rest of the small bowel.
Consequently, the motion of the duodenum is different
from the rest of the small bowel. This difference in motion
between radiation treatments produces differences in the
volume of tissue irradiated. To track these differences, the
relatively fixed duodenum should be contoured as a sepa-
rate structure from the more freely-moving remaining
small bowel
Our data further suggests that the complex motion of the
small bowel may be exploited for therapeutic benefit. The
Small bowel (excluding duodenum), and duodenum dose-vol- ume histograms for all available fractions in patients 4–6 Figure 2
Small bowel (excluding duodenum), and duodenum dose-vol-
ume histograms for all available fractions in patients 4–6.
Table 1: Listing of mean, minimum, and maximum CT volume, in cubic centimeters, of duodenum and small bowel (excluding 
duodenum) for all study patients.
Patient # Duodenum Volume Mean (Range) Non-duodenal Small Bowel Volume Mean (Range)
1 73 (58–110) 3182 (2062–3657)
2 111 (88–135) 1195 (1128–1261)
3 58 (55–62) 1435 (1337–1504)
4 44 (30–58) 954 (915–993)
5 32 (27–34) 1042 (989–1079)
6 31 (16–45) 1186 (1102–1335)
7 37 (31–44) 756 (673–867)
8 54 (21–120) 810 (721–1034)
9 8 (7–9) 655 (448–858)
Small bowel (excluding duodenum), and duodenum dose-vol- ume histograms for all available fractions in patients 1–3 Figure 1
Small bowel (excluding duodenum), and duodenum dose-vol-
ume histograms for all available fractions in patients 1–3.Radiation Oncology 2006, 1:33 http://www.ro-journal.com/content/1/1/33
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relative lack of anatomic attachments of the jejunum and
ileum allow for complex motion. The result of this
motion may be that irradiation of different segments of
this non-duodenal small bowel occurs during each frac-
tion. If different non-duodenal segments are being irradi-
ated daily, then no single segment may get the full
prescription dose. Therefore, dose escalation to the pan-
creas (using strategies such as implanted fiducial markers
and/or respiratory gating to allow small fields while still
allowing reliable tumor targeting despite motion) may be
possible without a concomitant increase in non-duodenal
small bowel toxicity.
Individual variations in our results make it impossible to
suggest dose volume limits for either duodenum or small
bowel. In fact, the individual variation in the data suggests
that general guidelines may lack utility. Thus, recommen-
dations may have to be individualized based on interfrac-
tion motion.
A trial of dose escalation, without chemotherapy, using
three dimensional conformal radiation therapy to 70–72
Gy was performed in 44 patients with locally advanced
pancreatic adenocarcinoma. The stomach and duodenum
was limited to 50 Gy; however, given the aforementioned
proximity to the pancreas, 30% of the duodenum was
allowed to exceed this limit. Forty-one patients received
the intended total dose. Treatment was never stopped
because of toxicity. Acute Grade 3 toxicity was seen in 9%
of patients. Late Grade 3 and Grade 4 gastrointestinal tox-
icity was seen in 3 patients and 2 patients, respectively.
Late (Grade 5) gastrointestinal bleeding was observed in 3
patients, 2 of whom had local tumor progression. Local
disease progression was observed in 44% of patients. No
true partial or complete responses were documented. The
median survival from the time of diagnosis was 10
months from the start of radiotherapy. Distant metastases
remained the major problem.[8]
The inability of 70 Gy to achieve local control may reflect
an insufficient dose or an inability to irradiate the pan-
creas due to organ motion. Well characterized by several
previously published reports, [2-4] our data (not shown)
also suggests that pancreatic motion is significant and
needs to be accounted for with any conformal technique.
We trust that existing and developing technology and
methodology will allow reliable irradiation of the pan-
creas with small fields despite organ motion. Existing lit-
erature shows dismal outcomes with conventional
therapy and the feasibility of dose escalation to 70 Gy.
Therefore trials of radiation dose escalation beyond the
conventional 50 Gy, possibly with concurrent chemother-
apy, remain reasonable in inoperable pancreatic cancer.
As issues relating to pancreatic motion are addressed, we
hope future pancreatic dose escalation studies will track
irradiated volume of duodenum separately from the
remainder of the small bowel and report correlations with
toxicity.
Conclusion
The volume of irradiated small bowel excluding duode-
num changes significantly between fractions of pancreatic
radiation therapy. These relatively large volume changes
suggest that dose escalation to the pancreas may be possi-
ble, as no single segment of non-duodenal small bowel is
likely to receive the full prescription dose. However, the
volume of irradiated duodenum is relatively more stable.
Therefore, dose/volume constraints on the duodenum
should be more stringent than for the remaining small
bowel.
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Small bowel (excluding duodenum), and duodenum dose-vol-
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